The role of leptin in the control of insulin-glucose axis by Marie Amitani et al.
REVIEW ARTICLE
published: 08 April 2013
doi: 10.3389/fnins.2013.00051
The role of leptin in the control of insulin-glucose axis
Marie Amitani*, Akihiro Asakawa , Haruka Amitani and Akio Inui
Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
Edited by:
Kevin W. Williams, The University of
Texas Southwestern Medical
Center, USA
Reviewed by:
Joachim Roth,
Justus-Liebig-University of Giessen,
Germany
Eric Berglund, The University of
Texas Southwestern Medical
Center, USA
*Correspondence:
Marie Amitani, Department of
Psychosomatic Internal Medicine,
Kagoshima University Graduate
School of Medical and Dental
Sciences, 8-35-1 Sakuragaoka,
Kagoshima, 890-8520, Japan.
e-mail: marisame@m3.kufm.
kagoshima-u.ac.jp
Obesity and diabetes mellitus are great public health concerns throughout the world
because of their increasing incidence and prevalence. Leptin, the adipocyte hormone, is
well known for its role in the regulation of food intake and energy expenditure. In addition
to the regulation of appetite and satiety that recently has attracted much attentions, insight
has also been gained into the critical role of leptin in the control of the insulin-glucose axis,
peripheral glucose and insulin responsiveness. Since the discovery of leptin, leptin has
been taken for its therapeutic potential to obesity and diabetes. Recently, the therapeutic
effects of central leptin gene therapy have been reported in insulin-deficient diabetes in
obesity animal models such as ob/ob mise, diet-induced obese mice, and insulin-deficient
type 1 diabetes mice, and also in patients with inactivating mutations in the leptin gene.
Herein, we review the role of leptin in regulating feeding behavior and glucose metabolism
and also the therapeutic potential of leptin in obesity and diabetes mellitus.
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INTRODUCTION
Obesity and diabetes mellitus are important public health con-
cerns throughout the world because of their increasing inci-
dence and prevalence. The pooled prevalence of obesity is
currently as high as 23.5%, and the general prevalence of dia-
betes among adults in the US is 6.3% (Sullivan et al., 2005).
Obese individuals have an increased risk of morbidity because
of the various related disorders, including diabetes, cardiovas-
cular events, stroke, cancer, and obstructive sleep apnea (Must
et al., 1999; Field et al., 2001; Polesel et al., 2009; Shah and Roux,
2009).
Food intake is controlled by a complex regulatory network
that depends on the central regulation of energy homeostasis. The
signals to regulate food intake are ultimately integrated or coordi-
nated by central mechanisms, particularly in the hypothalamus.
There are many factors to consider in the hypothalamic regula-
tion of food intake, and the interactions between adiposity and
the central neuropeptidergic cascade downstream of leptin are
increasingly being studied.
Since the discovery of leptin, it has been expected the ther-
apeutic potential for obesity and diabetes. Leptin is known as
a key appetite-regulating hormone, which effects on appetite,
energy expenditure, behavior, and glucosemetabolism.Much evi-
dence suggests that insulin and leptin act in the brain as adiposity
negative feedback signals (Morton and Schwartz, 2011).
Indeed, recent studies revealed that leptin has the effect to
normalize hyperglycemia and hyperinsulinemia and to increase
insulin sensitivity. (Kamohara et al., 1997).
The central leptin gene therapy has also been effective to
insulin-deficient diabetes in obesity animal models such as ob/ob
mise, diet-induced obese mice, and insulin-deficient type 1 dia-
betes mice (Kojima et al., 2009), and in patients with inactivating
mutations in the leptin gene (Farooqi et al., 1999). Thus, leptin
gene therapy is expected to be an effective therapeutic option for
obesity, and diabetes.
Herein, we review the role of leptin in regulating feeding
behavior and glucose metabolism and also the therapeutic poten-
tial of leptin in obesity and diabetes mellitus.
LEPTIN
Leptin is a 16-kDa protein hormone, which is secreted by
adipocytes. Plasma leptin concentration increases in propor-
tion to body fat mass, and regulate food intake and energy
expenditure to maintain body fat stores. (Zhang et al., 1994;
Campfield et al., 1995; Halaas et al., 1995; Pelleymounter et al.,
1995; Kamohara et al., 1997; Elias et al., 1999). Circulating lep-
tin is secreted into the blood-stream and reaches to the brain
through the brain-blood barrier (BBB) and cebrospinal fluid
(CSF) barrier. Leptin act in the hypothalamus, where leptin
inhibits neuropeptide Y (NPY) neurons and causes anorexia
(Elmquist et al., 1999). These will be discussed in the following
sections.
CENTRAL REGULATION OF FOOD INTAKE AND ENERGY
EXPENDITURE
The regulation of food intake is coordinated by central
mechanisms, particularly in the hypothalamus. The hypotha-
lamus plays an important role in regulating appetite and
energy expenditure. Particularly, the arcuate nucleus of
the hypothalamus arcuate nucleus (ARC) is critical for
appetite regulation and the mechanism of obesity. There
are many factors to consider in the hypothalamic regulation
of food intake, e.g., melanin-concentrating hormone (MCH),
NPY, agouti-related protein (AgRP), proopiomelanocortin
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(POMC), cocaine-and-amphetamine responsive transcript
(CART), oxytocin, arginine vasopressin, brain-derived neuro-
trophic factor (BDNF), serotonin (5-HT), corticotropin-
releasing factor (CRF) and the urocortins (UCN1, UCN2,
UCN3).
The ARC projects to other hypothalamic sites, such as the
periventricular nucleus (PVN), dorsomedial (DMH) hypothala-
mic nuclei, and the lateral hypothalamic area (LHA). The neurons
include POMC, NPY, and AgRP are located in ARC. The other
neurons include α-melanocyte–stimulating hormone (αMSH),
which are the melanocortin peptides that are derived from
POMC. NPY/AgRP neurons release the orexigenic peptides NPY
and AgRP, lead to increased food intake (Williams et al., 2011; Xu
et al., 2011). By contrast, POMC neurons synthesize and secrete
an anorexigenic peptide, α-MSH, which activates melanocortin
receptors and leads to decreased food intake. Central or periph-
eral administration of leptin increases POMC/CART mRNA
expression, and NPY and AgRP mRNAs are inhibited by leptin
administration.
The other important factors are CRF and 5-HT systems. CRF
and endogenous CRF receptor ligand urocortin are feeding-
inhibitory peptides localized at the PVN. Urocortin binds both
CRF type 1 and 2 receptors but shows a higher affinity for CRF
type 2 receptor than type 1 receptor. CRF type 2 receptors are
related to the stress-induced alterations of gastrointestinal func-
tions (Asakawa et al., 1999; Ushikai et al., 2011; Fujimiya et al.,
2012).
Central 5-HT systems also play an important role in the
suppression of feeding. Particularly, the 5-HT2C receptor (5-
HT2CR) and 5-HT1B receptors (5-HT1BRs) are widely expressed
in the central nervous system (CNS), mediating the anorexigenic
activity of endogenousmelanocortin receptor agonists and antag-
onists at the melanocortin 4 receptor (MC4R) (Lam et al., 2008;
Marston et al., 2011). 5-HT acts on 5-HT2CR in POMC neurons
to regulate feeding and insulin sensitivity via MC4R signaling
pathways (Zhou et al., 2007). 5-HT depletion does not impair
the anorectic effects of leptin, which suggests that leptin does not
directly cause CNS serotonin neurons to influence appetite (Lam
et al., 2011).
In the peripheral feed-regulating peptide, ghrelin act con-
versely with leptin. Ghrelin is an endogenous agonist at the
growth hormone (GH) secretagogue receptor and is a member
of the motilin-related family of regulatory peptides. In addition
to its ability to stimulate GH secretion and gastric motility, ghre-
lin stimulates appetite and induces a positive energy balance that
leads to weight gain. Leptin and ghrelin are complementary, yet
antagonistic, signals that reflect acute and chronic changes in
the energy balance. Endocrine and vagal afferent pathways are
involved in these actions of ghrelin and leptin (Inui et al., 2004).
Ghrelin activates NPY/AgRP neurons in the PVN and suppresses
POMC neuronal activity to regulate food intake (Cowley et al.,
2003). As to glucoregulatory functions, increased leptin levels are
associated with obesity and type 2 diabetes, while decreased ghre-
lin levels are associated with obesity and insulin resistance rather
than type 2 diabetes. Glucose infusion rate positively correlated
with plasma ghrelin and negatively correlated with serum leptin
levels (Zhang et al., 2012).
LEPTIN TRANSGENIC ANIMAL MODEL
The central or peripheral administration of leptin to rodents
reduces food intake and increases energy expenditure (Ahima
et al., 2000). In transgenic animal models, such as leptin-deficient
(ob/ob) mice and LepRb-deficient (db/db) mice, exhibit the
development of marked obesity, insulin resistance, hyperinsu-
linemia, impaired glucose homeostasis, and diabetes (Schwartz
et al., 1996; Cohen et al., 2001; McMinn et al., 2005). By contrast,
transgenic and brain-specific reconstitution of LepRb in db/db
mice improves obesity and daibetes. Fasting rodents with reduced
leptin levels and ob/ob mice exhibit decreased level of hypotha-
lamic POMC mRNA, which is normalized by exogenous leptin
administration that subsequently improves obesity and diabetes.
LEPTIN AND SYNAPTIC PLASTICITY
Recent findings suggest that leptin exerts plastic effects on neural
connections and that leptin might function as a developmen-
tal cue for brain development (Ahima et al., 1998; Bouret et al.,
2004). Leptin is required for normal development of ARC path-
ways, and this developmental activity of leptin is restricted to
a neonatal window of maximum sensitivity, which corresponds
to a period of elevated leptin secretion (Bouret and Simerly,
2004). Leptin levels during the perinatal period are crucial for
the development of metabolic systems that are involved in energy
homeostasis, food seeking and reward behaviors. Rodents exhibit
a postnatal leptin surge, in whitch circulating leptin levels increase
around postnatal day 5 and peak between postnatal day 9 and
10 (Granado et al., 2011, 2012). In animal studies, the treat-
ment of rodents with exogenous leptin does not affect milk
intake or metabolic rates until after weaning (Mistry et al., 1999;
Proulx et al., 2002). Blocking the postnatal leptin surge results
in long-term leptin insensitivity and increased susceptibility to
diet-induced obesity during adulthood (Attig et al., 2008). The
offspring of obese rats display an amplified and prolonged neona-
tal leptin surge, which is accompanied by elevated leptin mRNA
expression in their abdominal white adipose tissue (Kirk et al.,
2009). Maternal undernutrition markedly reduces the postnatal
surge of plasma leptin, which particularly disturb the hypothala-
mic wiring and the gene expression of the anorexigenic POMC
neurons (Delahaye et al., 2008). In the absence of leptin, the
AgRP/NPY and α-MSH pathways are severely disrupted in adult
ob/ob mice (Bouret and Simerly, 2004). By contrast, when lep-
tin is delivered systemically to ob/ob mice, the synaptic density
rapidly normalizes; effect is detectable within 6 hour, which is
several hours before leptin’s effect on food intake (Pinto et al.,
2004). In the obesity and hyperleptinemic rat, phenotype impaird
hippocampal synaptic plasticity (Grillo et al., 2011a,b).
LEPTIN SIGNALING
LEPTIN ISOFORMS
Leptin exert its antiobesity effect via leptin receptor (LepR) in
(ARH) (Fei et al., 1997; Bouret and Simerly, 2004). There are
six isoforms of LepRs (OB-R): OB-Ra, OB-Rb, OB-Rc, OB-Rd,
OB-Re, and OB-Rf (Fruhbeck, 2006). The short form of LepR is
widely expressed in multiple tissues (Elmquist et al., 1998). The
longer form of the LepR encodes a protein with a longer cytoplas-
mic domain (OB-Rb). OB-Rb is a member of the class 1 cytokine
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receptor family and considered the main isoform involved in
the transduction of intra cellular signals (Mantzoros et al., 2011;
Marroqui et al., 2012). OB-Rb is expressed highly in PMV, ARH,
DMH, VMH, MEPO (medial preoptic nucleus) (Gautron and
Elmquist, 2011).
JAK/STAT PATHWAY
Leptin signaling via the long form of OB-Rb is intracellularly cou-
pled with the janus kinase (JAK)–signal transducer and activator
of transcription (STAT) pathway (Jak/STAT pathway). Leptin
binds to OB-Rb and activates the receptor-associated kinase
JAK2 via transphosphorylation and phosphorylates three tyrosine
residues (Y985, Y1077, and Y1138 in mice). The signals emanat-
ing from the LepR Tyr985 control hepatic insulin sensitivity. Lack
of LepRb-Tyr985 signaling enhances whole-body insulin sensi-
tivity partly through increased suppression by insulin of hepatic
glucose production. Leptin stimulates JAK2-dependent phospho-
rylation and nuclear translocation of the transcription factor
signal transducer and activator of STAT3 and STAT5 the phospho-
rylated Y1138 on LepRb. This JAK2/STAT3 pathway is required
for leptin control of energy balance and body weight. pSTAT3
translocates to the nucleus, where it increase the expression of
POMC and inhibits that of NPY (St-Pierre and Tremblay, 2012)
(Figure 1). Defects in leptin signaling lead to leptin resistance,
which is a primary risk factor for obesity.
STAT3 regulates glucose homeostasis by suppressing the
expression of gluconeogenic genes in the liver. Plasma insulin
stimulates tyrosine phosphorylation of STAT3 in the liver, and
hepatic IL-6 that is induced by the brain-insulin action is nec-
essary for the activation of STAT3 (Inoue et al., 2006). The
suppressed hepatic glucose production and expression of glu-
coneogenic genes induced by intracerebral ventricular insulin
infusion is impaired in liver-specific STAT3 deficiency mice and
in IL-6 deficient mice (Inoue et al., 2006). These results demon-
strate that IL-6-STAT3 signaling in the liver contributes to insulin
action in the brain, which suppresses hepatic glucose production.
PI3K
Another important pathway is PI3K. JAK2 stimulates the phos-
phorylation of insulin receptor substrate (IRS) 1 or 2. IRS then
activates PI3K, leading to the production of phosphatidylinositol
3, 4, 5-triphosphate (PIP3). PIP3 formation activates Akt, which
subsequently prevents Forkhead box O (FoxO)-1 from inhibiting
the expression of POMC and from stimulating the expression of
NPY and AgRP. Overall, PI3K promotes the effects of leptin by
inhibiting FoxO1 (Wauman and Tavernier, 2011; St-Pierre and
Tremblay, 2012). A mutation in the gene encoding the protein
kinase AKT2/PKB-β reveals the autosomal dominant inheritance
of severe insulin resistance and diabetes mellitus (George et al.,
2004). The level of Sirt1 protein is increased in the hypothalamus
during feeding, which decreases the FoxO1-dependent expres-
sion of AgRP and results in the cessation of feeding (Sasaki et al.,
2010).
SOCS3
Recently, a new family of molecules, called suppressors of
cytokine signaling (SOCS), has been identified. Leptin-induced
FIGURE 1 | Leptin binds to the leptin receptor (LepRb) and activates
the receptor-associated kinase JAK2 via transphosphorylation and
phosphorylates three tyrosine residues (Y985, Y1077, and Y1138).
Leptin-induced mRNA expression of JAK-STAT is inhibited by SOCS3.
Insulin and leptin regulate the expression of AgRP and POMC via Foxo1 and
signal transducer and activator of transcription factor Stat3. Sirt1
suppresses the Foxo1-dependent expression of the orexigenic
neuropeptide AgRP. AgRP, agouti-related protein; FOXO1, Forkhead box O1;
IRS, insulin receptor substrate; PI3K, phosphatidylinositol 3 kinase; PIP3,
phosphatidylinositol 3, 4, 5-triphosphate.
mRNA expression of JAK-STAT is inhibited by SOCS3 in insulin
(INS)-1 β-cells and human pancreatic islets in vitro and in the
pancreatic islets of ob/ob mice in vivo (Laubner et al., 2005).
SOCS3 inhibits basal and STAT3/5b-dependent rat preproinsulin
1 gene promoter activity in INS-1 cells (Laubner et al., 2005).
The SOCS molecules might play an important role in the devel-
opment of leptin resistance that is observed in the CNS and in
the endocrine pancreatic beta-cells during obesity (Seufert, 2004).
These results indicate that SOCS3 represents a transcriptional
inhibitor of preproinsulin gene expression, which is induced by
leptin via JAK-STAT3/5b signaling in pancreatic β-cells (Laubner
et al., 2005).
PHOSPHATASES
There are five main phosphatases involved in leptin signal-
ing: SHP2, PTEN, PTP1B, and the recently implicated TCPTP
and RPTP epsilon. With the exception of SHP2 that globally
promotes leptin signaling by coupling to ERK kinase, the other
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four phosphatases work by inhibiting leptin signaling (St-Pierre
and Tremblay, 2012).
Phosphatase and tensin homolog deleted on chromosome 10
(PTEN) is a class 1 Dsp known mainly for its tumor suppressor
functions (Julien et al., 2011). PTEN plays an important role in
leptin signaling because it is a negative regulator of the PI3K path-
way (St-Pierre and Tremblay, 2012). By enhancing insulin-PI3K
signaling via deletion of PTEN, β-cell mass and function lead to
increase. PTEN expression in islets was upregulated in both mod-
els of type 2 diabetes. PTEN exerts a critical negative effect on
both β-cell mass and function (Wang et al., 2010a).
LEPTIN RESISTANCE
Although current pharmacological and behavioral treatments for
obesity cause initial weight loss, this effect is transient and gen-
erally followed by weight regain, which is associated with leptin
resistance (Yanovski and Yanovski, 2002). Despite an increase in
plasma leptin levels, rats that are fed a high-fat diet become obese
(Akiyama et al., 1996).
The mechanism of leptin resistance has been revealed. The
first cause of leptin resistance is impaired leptin transport across
the BBB. The second cause of leptin resistance is impaired lep-
tin signal transduction in neurons, including SOCS3, PTP1B.
As the other mechanism, the hypothalamic inflammation, the
role of endoplasmic reticulum stress and defective autophagy are
suggested to be involved.
Leptin transport across the BBB is impaired in obesity
(Burguera et al., 2000). The permeability of the BBB to leptin
is decreased in high-fat diet-induced obese rats despite increased
plasma leptin levels (Burguera et al., 2000). OB-Ra and OB-Rc are
highly expressed in the choroid plexus and microvessels, where
these receptors are assumed to play a role in leptin uptake or efflux
from the cerebrospinal fluid (CSF) and in receptor-mediated
transport of leptin across the BBB (Hileman et al., 2002); by con-
trast another study indicates that leptin transport across the BBB
is not mediated by a product of the LepR gene (Banks et al., 2002).
Hyperleptinemia, which either manifests gradually in associa-
tion with age-related obesity or is produced rapidly by the con-
sumption of energy-enriched diets, is associated with decreased
brain leptin concentrations in rodents and humans (Banks et al.,
1999; Burguera et al., 2000; Banks and Farrell, 2003; Banks
et al., 2006; Suzuki et al., 2008; Ziylan et al., 2009; Kalra, 2011).
Increased blood levels of leptin fail to reduce feeding or to be
reflected in increased levels of leptin in the CSF. If leptin is
delivered directly into the brain, it reduces feeding, but deliv-
ery into the blood is essentially without effect (Kastin and Pan,
2006). Insufficient leptin signaling in the hypothalamus, which is
caused by either decreased availability of leptin for transport to
the hypothalamus (in the case of leptinopenia), or restricted lep-
tin entry across the BBB (imposed by hyperleptinemia in obese
subjects), is primarily responsible for inducing hyperglycemia
and hyperinsulinemia; the persistence of these pathophysiologic
sequelae culminates in diabetes mellitus (Kalra, 2011; Figure 2).
LEPTIN AND GLUCOSE METABOLISM
Leptin plays an important role to regulate energy balance and also
affects peripheral glucose homeostasis and locomotor activity.
There are notable reports to discuss the leptin and glucose
metabolism. The ARC has been proposed as an important site
of leptin action. Unilateral restoration of leptin signaling in the
ARC of LepR null allele [Lepr (neo/neo) mice] leads to a modest
decrease in body weight and food intake. In contrast, unilateral
reactivation markedly improved hyperinsulinemia and normal-
ized blood glucose levels and locomotor activity (Coppari et al.,
2005). These data demonstrate that ARC in the brain have the role
to mediate the antidiabetec actions of leptin in models of type 2
diabetes.
In the other study, the expression of ObRb only in POMC neu-
rons leads to a marked decrease in energy intake and a modest
reduction in body weight (Huo et al., 2009). The blood glucose
levels are normalized independent of changes in food intake and
body weight. Furthermore, physical activity is greatly increased
despite profound obesity. These results suggest that leptin signal-
ing in POMC neurons in the ARC is crucial to stimulate activity
and prevent diabetes in db/db mice (Huo et al., 2009).
Leptin and insulin signaling regulate food intake by control-
ling the expression of orexigenic and anorexigenic neuropeptides
in ARH via FoxO1 and the STAT-3. Insulin regulates the activity
of the Forkhead transcription factor (Foxa-2) by Akt-mediated
phosphorylation (Wolfrum et al., 2003). Foxa2 is a downstream
target of insulin-signaling and plays an important role in the
integration of metabolic signals, adaptive behavior and phys-
iological responses (Silva et al., 2009). Foxa2 binds to MCH
and orexin promoters and stimulates their expression, which
leads to increased food consumption, metabolism and insulin
sensitivity.
AMP-activated protein kinase (AMPK) is an intracellular
energy sensor and regulator of food intake. AMPK regulates
food intake by responding to hormonal and nutrient signals
in the hypothalamus (Minokoshi et al., 2004). AMPK regulates
energy expenditures by modulating NAD+ metabolism and sir-
tuin1 (Sirt1) activity (Canto et al., 2009). AMPK also regulates
energy levels by switching off ATP-consuming pathways and
switching on ATP-producing pathways, such as glucose uptake
and fatty acid oxidation. Leptin inhibits hypothalamic AMPK
activity and restricts food intake. There are four mechanisms
to be considered: first, ghrelin stimulates AMPK in NPY/AgRP
in the arcuate nucleus and in the ventromedial hypothalamic
nucleus and activates an AMPK-dependent presynaptic pathway
that sustains AgRP neuron firing via a local synaptic memory sys-
tem. Second, adiponectin stimulates hypothalamic AMPK. Third,
hypothalamic AMPK controls energy expenditures via thyroid
hormone or leptin (Stark et al., 2013). Leptin treatment sig-
nificantly suppresses NPY secretion in the cells. Leptin inhibits
AMPK activity and activates acetyl-coenzyme acarboxylase in
NPY neurons.When AMPK is inhibited by compound C or phos-
phatidylinositol 3 kinase (PI3K), the leptin-mediated decrease in
NPY secretion is prevented (Dhillon et al., 2011).
Defects in glucose sensing also result in obesity. Glucose star-
vation inhibits the ability of leptin to stimulate tyrosyl phospho-
rylation and inhibits the activation of JAK2 and STAT3 in vitro
(Su et al., 2012). Glucose dose-dependently enhances leptin sig-
naling. By contrast, glucose does not enhance GH-stimulated
phosphorylation of JAK2 and STAT5 (Su et al., 2012). Glucose
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FIGURE 2 | Circulating leptin is correlated with the degree of adiposity
and is transported across the blood-brain barrier (BBB). In hypothalamus,
leptin activates POMC and CART neurons, and inhibit NPY and AgRP
neurons, lead to anorexia. Leptin has effect to feeding behavior, appetite,
insulin-glucose axis, and cognitive function. (A) In leptin sensitive individuals,
leptin inhibits insulin biosynthesis and secretion from pancreatic β-cells. By
contrast, insulin stimulates leptin secretion from adipose tissue. Leptin
stimulates hepatic gluconeogenesis and hepatic insulin sensitivity via the
hepatic branch of the vagus nerve. Additionally, leptin increases glucose
uptake in the skeletal muscle, heart, and brown adipose tissue (BAT) via the
sympathetic nervous system. (B) In leptin resistant over-weight individuals,
the permeability of the BBB to leptin is decreased in high-fat diet-induced
obesity despite the increase in plasma leptin levels. This impaired transport
of leptin across the BBB is one of the causes of leptin resistance.
Insufficiency of leptin signaling in the hypothalamus (induced by
hyperleptinemia in obese subjects), causes hyperglycemia and
hyperinsulinemia, which lead to diabetes mellitus. AgRP, agouti-related
protein; ARC, arcuate nucleus; CART, cocaine-and-amphetamine responsive
transcript; LHA, lateral hypothalamic area; NPY, neuropeptide Y; POMC,
proopiomelanocortin; BBB, blood-brain barrier.
starvation or 2-deoxyglucose induced inhibition of glycolysis acti-
vates AMPK and inhibits leptin signaling. The inhibition of
AMPK restores the ability of leptin to stimulate STAT3 phospho-
rylation. AMPK inhibits leptin signaling and blocks the ability of
glucose to enhance leptin signaling (Su et al., 2012).
Sirt1 improves insulin sensitivity in vitro. In an animal model,
hypothalamic Sirt1 protein increases food intakes, and this effect
is shown in diet-induced obese mice and db/db mice. Forced
expression of wild-type Sirt1 in the mediobasal hypothalamus
by adenovirus microinjection suppresses FoxO1-induced hyper-
phagia, which is a model for central insulin resistance (Sasaki
et al., 2010). FoxO1 is a transcription factor that controls liver
metabolism and pancreatic β-cell function. The expression of
the genes encoding AgRP and POMC neuropeptides is reg-
ulated by insulin and leptin via Foxo1 and the STAT factor
Stat3 (Kitamura et al., 2006). Hypothalamic Sirt1 protein levels
increase during feeding, and the forced expression of wild-type
Sirt1 in the mediobasal hypothalamus suppresses FoxO1-induced
hyperphagia. Sirt1 suppresses AgRP promoter activity, which
leads to decreased FoxO1-dependent expression of orexigenic
neuropeptide AgRP and the cessation of feeding (Nakae et al.,
2006; Sasaki et al., 2010). Resveratrol is a pharmacological acti-
vator of Sirt1, which improves the life span and health of mice
that are fed a high fat diet (Baur et al., 2006). Resveratrol acti-
vates Sirt1 activity and suppress the FoxO1-dependent expression
of the orexigenic neuropeptide AgRP (Sasaki et al., 2010).
glycemia in a specific mouse model of type 2 diabetes MKR
(transgenic overexpression of a skeletal muscle dominant-
negative IGF-I receptor with a lysine-to-arginine amino acid).
Leptin treatment enhanced hepatic insulin sensitivity of the MKR
mice by suppression of hepatic glucose production during the
hyperinsulinemiceuglycemic clamp. Additionally, leptin reduced
gene expression of key regulator of glucose metabolism such as
G6Pase, a gluconeogenic enzyme in liver (Toyoshima et al., 2005).
THE EFFECT OF LEPTIN ON LIVER AND PERIPHERAL TISSUES
In humans and in rodents, various OB-R isoforms are widely
distributed in many organs, including the pancreas, liver, heart,
kidney, adipose tissue, and brain. Leptin regulates glucose
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homeostasis and hepatic insulin sensitivity, as well as food intake
and energy expenditures by activating the long form of the
LepRb. The central administration of leptin increases glucose
turn-over and glucose uptake in peripheral tissues, [such as the
skeletal muscle, heart, and brown adipose tissue (BAT)], via the
sympathetic nervous system.
Leptin stimulates hepatic gluconeogenesis and hepatic insulin
sensitivity via the hepatic branch of the vagus nerve. In LepR-
deficient Koletsky rats, the adenovirally induced expression of
LepRs in ARC nucleus improves peripheral insulin sensitivity
via enhanced suppression of hepatic glucose production, with
no change in insulin-stimulated glucose uptake or disposal. This
effect is associated with increased insulin signal transduction
via phosphatidylinositol-3-OH kinase in the liver (but not in
the skeletal muscle) and with reduced hepatic expression of
the gluconeogenic genes, glucose-6-phosphatase and phospho-
enolpyruvate kinase (German et al., 2009). Moreover, the effects
of hypothalamic leptin signaling on hepatic insulin sensitivity are
blocked by selective hepatic vagotomy, which suggests that the
effect of hypothalamic leptin on the liver is dependent on the
hepatic branch of the vagus nerve (German et al., 2009).
Leptin, insulin, and nutrient-related signals in the CNS
improve hepatic insulin sensitivity however, the mechanism by
which CNS leptin signaling normalizes diabetic hyperglycemia
and whether this process involves leptin-dependent effects on
hepatic glucose production or tissue glucose uptake are unknown
(German et al., 2011). Leptin action in the brain potently sup-
presses hepatic glucose production while increasing tissue glucose
uptake despite persistent, severe insulin deficiency (German et al.,
2011). The hyperinsulinemia in ob/ob mice might be caused
by the impairment of leptin signaling in pancreatic β-cells and
contributes to obesity and insulin resistance. The polyethylene
glycolylated mouse leptin antagonist (PEG-MLA)-treated mice
exhibit increased fasting and glucose stimulated plasma insulin
levels, decreased whole-body insulin sensitivity, elevated hepatic
glucose production, and impaired insulin-mediated suppression
of hepatic glucose production (Levi et al., 2011).
The decrease of body fat stores in uncontrolled insulin-
deficient diabetes results in marked reduce of plasma leptin
levels (German et al., 2010). Physiologic leptin replacement pre-
vents insulin resistance in uncontrolled diabetes via a mecha-
nism unrelated to changes in food intake or body weight. This
effect is associated with reduced total body fat and hepatic
triglyceride content, preservation of lean mass, and improved
insulin signal transduction via the insulin receptor substrate-
phosphatidylinositol-3-hydroxy kinase pathway in the liver, but
not in skeletal muscle or adipose tissue (German et al., 2010).
Although physiologic leptin replacement lowers blood glucose
levels only slightly, it fully normalizes elevated plasma glucagon
and corticosterone levels and reverses the increased hepatic
expression of gluconeogenic enzymes characteristic of rats with
uncontrolled diabetes (German et al., 2010). Furthermore, the
effect of VMH leptin infusion on muscle glucose uptake is depen-
dent on melanocortin signaling because melanocortin antago-
nists blocked the response to leptin (Toda et al., 2009).
In adult humans, BAT is contained along the spine and behind
the muscles of the lower neck and collarbone. BAT is activated
by various stimuli, including exposure to cold, and stimulates
the metabolism of fat and sugars. This process is more obvi-
ous in the young and lean than in the old and obese, and in
women rather than in men (Farmer, 2009). Subsequent to the
subcutaneous transplantation of embryonic BAT, type 1 diabetes
in streptozotocin-treated mice (which is associated with severely
impaired glucose tolerance and significant loss of adipose tissue)
is improved (Gunawardana and Piston, 2012). BAT transplanta-
tion results in euglycemia, normalized glucose tolerance, reduced
tissue inflammation, and the reversal of clinical diabetes mark-
ers such as polyuria, polydipsia, and polyphagia (Gunawardana
and Piston, 2012). These effects are independent of insulin but
correlate with the recovery of the animals’ white adipose tissue
(Gunawardana and Piston, 2012). In uncontrolled diabetes, icv
administration of leptin activates BAT, which leads to normalize
blood glucose levels in STZ-induced diabetic rats. The suggested
mechanism is that central leptin increases the glucose uptake to
BAT, which is accompanied by the return of reduced plasma thy-
roxine (T4) levels and BAT uncoupling protein-1 (Ucp1) mRNA
levels (Matsen et al., 2013).
EFFECTS OF LEPTIN ON PANCREATIC β-CELLS
LepRs are present in pancreatic β-cells, and leptin inhibits insulin
biosynthesis and secretion from pancreatic β-cells. By contrast,
insulin stimulates leptin secretion from adipose tissue. This hor-
monal regulatory feedback loop is an important adipo-insular
axis. Dysfunction of this adipo-insular crosstalk plays an impor-
tant role in the development of hyperinsulinemia and type
2 diabetes mellitus.
Leptin directly affects pancreatic β-cell gene expression and
leads to decrease insulin secretion (Seufert et al., 1999; Seufert,
2004). Furthermore, leptin affects the β-cell mass via changes in
proliferation, apoptosis, and cell growth (Marroqui et al., 2012).
Leptin suppresses the expression of preproinsulin mRNA in
pancreatic β-cells. In the presence of the incretin hormone
glucagon-like peptide-1 (GLP-1), which stimulates the proinsulin
gene promoter, leptin inhibits the GLP-1-induced expression of
preproinsulin mRNA in human islets (Seufert, 2004). Leptin sup-
pressed GLP-1-stimulated intracellular Ca2+ concentrations, lead
to decrease insulin secretion. In contrast, the ObR-KO islets were
not response to leptin (Morioka et al., 2012).
Several signaling pathways are involved in this inhibitory role
of leptin in insulin secretion. Leptin inhibits glucose transport via
glucose transporter 2 (GLUT-2), thus inhibiting the subsequent
events in the stimulus–secretion coupling. Leptin also activates
the PI3K-dependent reorganization of the actin cytoskeleton,
which opens of the KATP channels. Furthermore, leptin inhibits
insulin secretion by PI3K-dependent activation of phosphodi-
esterase 3B (PDE3B) and by decreased cAMP levels, thus inhibit-
ing the protein kinase A (PKA) pathway, which is regulates Ca2+
channels and exocytosis (Marroqui et al., 2012).
PP-1alpha, the catalytic subunit of protein phosphatase 1
(PP-1), has recently been characterized genetically as a candi-
date gene for type 2 diabetes. PP-1 is a key enzyme in the
insulin-signaling cascade in the muscles and liver. Expression
of PP-1alpha has been verified in human pancreatic sections.
PP-1alpha mRNA and protein expression is down-regulated by
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leptin, which culminates in the reduction of PP-1 enzyme activity
in INS-1 pancreatic β-cells (Kuehnen et al., 2011).
The regulation of β-cell mass, (including proliferation, neoge-
nesis, cell size, and apoptosis), is essential for the compensatory
response of the endocrine pancreas to increase insulin demand,
such as occurs in obesity (Marroqui et al., 2012). The prolifera-
tive effects, as well as the antiapoptotic, and proapoptotic effects,
of leptin have been observed to regulate the β-cell mass (Marroqui
et al., 2012).
Thus, further studies are necessary to determine the role of
leptin in the regulation of β-cell mass and glucose metabolism.
LEPTIN AND GENE THERAPY
Leptin has been recognized as one of the therapeutic candidates
for obesity and as a regulator of fat mass, but its therapeutic effect
is limited because of the apparent development of leptin resis-
tance and the decreased BBB transport that is, observed in obese
subjects with elevated blood leptin levels. In recent studies, a sin-
gle, central administration of recombinant adeno-associated virus
vector encoding the leptin gene severely depletes fat and amelio-
rates the major symptoms of metabolic syndrome for extended
periods in rodents (Kalra and Kalra, 2005).
Leptin therapy has been found to reverse hyperglycemia and
to prevent mortality in several rodent models of type 1 dia-
betes (Chinookoswong et al., 1999; Yu et al., 2008; Fujikawa
et al., 2010; Wang et al., 2010b,c; Denroche et al., 2011).
Intracerebroventricular (icv) infusion of leptin reverses and
greatly improves hyperglycemia, hyperglucagonemia, hyperke-
tonemia, and polyuria caused by insulin deficiency in mice.
Furthermore, icv leptin delivery improves expression of the
metabolically relevant hypothalamic neuropeptides POMC, NPY,
and AgRP in type 1 diabetes mice (Fujikawa et al., 2010). Leptin
administration improves skeletal muscle insulin responsiveness in
diet-induced insulin-resistant rats (Yaspelkis et al., 2001).
Selectively increased leptin transgene expression is induced by
a single icv injection of adeno-associated viral vectors encod-
ing leptin (rAAV-lep). An injection of recombinant adenovirus
encoding leptin cDNA (Ad-lep) causes hyperleptinemia and sup-
presses weight gain, body fat, and blood insulin levels in normal
rats and ob/ob mice (Chen et al., 1996; Muzzin et al., 1996). By
contrast, recombinant methionyl human leptin (r-metHuLeptin)
is a recombinant analog of human leptin that is composed of
the 146 aminoacids of mature human leptin with an additional
methionyl residue at the N-terminal end of the recombinant pro-
tein. The difference between the two therapeutic approaches is the
continuous chronic secretion of leptin mediated by gene delivery
versus the intermittent bolus delivery and rapid clearance of daily
injection of rh-leptin protein (Morsy et al., 1998). The compar-
ison of daily injection of recombinant leptin protein (rh-leptin)
and adenovirus-mediated delivery of the murine or human lep-
tin gene (Ad-leptin) for treatment of obesity in the ob/ob mouse
model reveals that the rate of weight loss and the percentage sati-
ety were significantly higher in the mice treated with Ad-leptin
(Morsy et al., 1998). Adeno-associated viral vectors are particu-
larly well suited for central leptin gene therapy because of thetr
low toxicity and their ability to drive transgenice expression for
extended periods (Wang et al., 2010c).
The enhanced leptin transgene expression is evoked by injec-
tion of rAAV-lep into various hypothalamic sites, including the
LHA, ARC, and PVN (Koyama et al., 1998; Muzzin et al., 2000).
Toda et al. demonstrated that leptin injection into the VMH
increases glucose uptake into the skeletal muscle, BAT, and heart;
by contrast, injection into the ARC increases glucose uptake in the
BAT, with no effect on glucose uptake in the DMH or the PVH
(Toda et al., 2009).
A single icv injection of rAAV-lep enhances leptin transgene
expression in the hypothalamus and promptly restores eug-
lycemia that persists along with severe insulinopenia throughout
a 7-week period of observation in twomonogenic diabetic models
the insulin-deficient non-obese Akita mice and the hyperinsu-
linemic, leptin-deficient, obese ob/ob mice (Ueno et al., 2006).
The enhanced leptin transgene expression depletes adipose tis-
sue and depresses weight gain by increasing energy expenditures
(White et al., 2000; Dhillon et al., 2001a,b; Bagnasco et al., 2002;
Dube et al., 2002; Wang et al., 2010c). The injection of rAAV-lep
increases hypothalamic leptin expression and moderates diet-
induced hyperglycemia, hyperinsulinemia, and skeletal muscle
insulin resistance (Buettner et al., 2000; Bagnasco et al., 2003; Lee
et al., 2004).
The therapeutic effects of central leptin gene therapy have been
reported in insulin-deficient diabetes and in obesity animal mod-
els, such as ob/ob, diet-induced obese mice, insulin-deficient type
1 diabetes mice, and insulin-dependent diabetes animals (Akita
mice) (Dube et al., 2002; Ueno et al., 2004, 2006; Yu et al., 2008;
Kalra, 2009; Kojima et al., 2009; Naito et al., 2011). LepTg:Akita
mice, which are Akita mice with physiological hyperleptine-
mia, maintain normoglycemia, insulin hypersensitivity, improved
glucose tolerance, normal levels of plasma glucagon, and uri-
nary albumin excretion rates; furthermore, these animals exhibit
improved longevity (Naito et al., 2011).
Leptin administration rapidly decreases plasma gastric ghrelin
and adipocyte adiponectin. Ghrelin administration readily stim-
ulates feeding in control animals, which is completely ineffective
in rAAV-lep-treated wt mice. Thus, leptin that is locally expressed
in the hypothalamus counteracts the central orexigenic effects of
peripheral ghrelin (Ueno et al., 2004).
This long-term benefit on glucose homeostasis is not due
to diminished energy consumption, weight and adiposity but
is conferred by at least two mechanisms. First, enhanced glu-
cose metabolism to meet the demand for the rAAV-lep-induced
increased non-shivering thermogenesis mediated by BAT, and
second, insulin hypersensitivity (Ueno et al., 2006).
Investigators recently attempted the intranasal administration
of leptin in rats with diet-induced obesity. The intranasal admin-
istration of peptides for treating a disorders originating in the
brain is not a novel concept, but only the vasopressin analog
desmopressin has been used clinically by this route for sev-
eral decades to treat diabetes insipidus (Kastin and Pan, 2006).
Intranasal leptin induces significant weight loss and reduction of
adipose tissue mass in lean and diet-induced obesity rats, which is
consistent with the results of central leptin administration (Schulz
et al., 2012).
Taken together, increased leptin action in the hypothalamus
can induce euglycemia independent of pancreatic insulin, and
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central leptin reinforcement. These studies indicate that leptin
is therapeutically useful for the long-term treatment of insulin-
deficient diabetes and diet-induced obesity, serving as a newer
adjunct therapy for treating type1 and type2 diabetes.
CLINICAL TRIAL OF LEPTIN REPLACEMENT THERAPY
The first genetic evidence of congenital leptin deficiencies in
humans with severe obesity emerged in 1997 (Montague et al.,
1997). Twenty patients with congenital leptin deficiencies have
been identified worldwide. Their serum leptin levels were very
low despite their markedly elevated fat mass, and they presented
with morbid obesity, hypertension, dyslipidemia, hyperinsuline-
mia, insulin resistance, and hypogonadism. Most of the patients
are currently on r-metHuLeptin therapy (Vatier et al., 2012). In
these subjects, r-methuLeptin reduced food intake via neural cir-
cuits that reduce the cognition of food reward and enhance the
response to satiety signals (Farooqi et al., 2002, 2007; Vatier et al.,
2012). After therapy with r-metHuLeptin, the adult and pediatric
patients exhibited beneficial changes in their body weight, body
composition, endocrine function, immunity, and neurocognitive
domains (Farooqi et al., 2002; Licinio et al., 2004; Williamson
et al., 2005; Paz-Filho et al., 2011). The treatment produced dra-
matic weight loss in all three adults, corresponding to a reduction
of 44–53% of baseline weight, with a preferential loss of fat. The
subjects also exhibited improvements of their disordered neu-
roendocrine function, including the resolution of type 2 diabetes
mellitus and hypogonadism and beneficial effects on ingestive
and non-ingestive behaviors (Licinio et al., 2004; Williamson
et al., 2005).
Three leptin-deficient adults with a missense mutation of the
leptin gene were evaluated during treatment with recombinant
methionyl human leptin (r-metHuLeptin), and the therapy was
found decrease insulin resistance (Paz-Filho et al., 2008a). The
other study investigated the effects of leptin replacement on the
macro- and micronutrient preferences in leptin-deficient adults.
After leptin replacement, all the patients initially presented a
marked reduction in the intake of macro- and micro-nutrients,
and their mean daily caloric intake dropped to 50% with a shift
toward a higher percentage consumption of fats and a decrease
in the intake of carbohydrates (Licinio et al., 2007b). The other
patients were studied while off and on leptin therapy at a stable
body weight, and significant differences were measured in their
levels of macronutrients, vitamins, and minerals (Licinio et al.,
2007a).
The mechanism by which the rewarding properties of food
interact with physiological satiety signals and promote overeat-
ing has not been fully elucidated. Two human patients with
congenital leptin deficiencies were shown images of food before
and after 7 days of leptin replacement therapy, and their brain
responses weremeasured by functional magnetic resonance imag-
ing (fMRI). Leptin was found to modulate neural activation in
key striatal regions, suggesting that this hormone acts on neu-
ral circuits governing food intake to diminish the perception of
food reward while enhancing the response to satiety signals that
are generated during food consumption (Farooqi et al., 2007). In
the other study, during the viewing of food-related stimuli, lep-
tin replacement reduced brain activation in the regions linked to
hunger (insular, parietal, and temporal cortices) while enhanc-
ing activation in the regions linked to inhibition and satiety, as
measured by fMRI (Baicy et al., 2007). In addition to its role
in metabolism, treatment with r-metHuLeptin causes changes in
the neurocognitive domains, suggesting that leptin might play a
cognitive-enhancing role in the developing CNS (Paz-Filho et al.,
2008b).
The reported indications for r-metHuLeptin therapy include
leptin deficiency syndrome and lipodystrophic syndrome linked
to inactivating mutations in the leptin gene, hypothalamic amen-
orrhea, lipodystrophic syndrome (genetic, acquired, or linked to
HIV infection) and highly active antiretroviral therapy-induced
lipoatrophy (Lee et al., 2006; Brennan et al., 2009; Mulligan et al.,
2009).
There are few clinical reports on the effect of leptin therapy
on diabetes. Two patients with type1 diabetes with hypoleptine-
mia associated with acquired lipodystrophy were administered
r-metHuLeptin. After 1 year of leptin therapy, their glycemic con-
trol improved (Park et al., 2008). In the other clinical study, two
lipoatrophic diabetes patients received leptin therapy. Both sub-
jects exhibited extremely low amount of body fat and decreased
leptin concentrations. After the initiation of leptin therapy, their
fasting plasma glucose levels normalized, and their level of gly-
cosylated hemoglobin were reduced at 4 months and remained
below 6.5% for a full year (Ebihara et al., 2004). In obese patients
with type 2 diabetes and hyperleptinemia, r-metHuLeptin admin-
istration did not alter the body weight but marginally reduced the
level of HbA1c (Moon et al., 2011).
Future long-term studies are necessary to evaluate the efficacy
of leptin therapy in type 1 and type2 diabetes.
PERSPECTIVE OF LEPTIN THERAPY: LEPTIN AND COGNITIVE
FUNCTION
Recent studies have demonstrated that obesity is associated with
an increased risk of depression (Roberts et al., 2003). Leptin
changes the brain structure, neuron excitability, and synap-
tic plasticity. Leptin replacement (r-metHuLeptin) increased the
concentration of gray matter in the anterior cingulate gyrus, infe-
rior parietal lobule, and cerebellum, and markedly reduced body
weight in the three genetically leptin-deficient adults who had
recessive mutations in their ob genes (Matochik et al., 2005).
These effects of leptin are dramatically plastic, reversible, and
regionally specific in the human brain morphology (London
et al., 2011). In addition to its role in metabolism, leptin might
affect cognition and mood in the developing CNS. The impaired
leptin activity in the hippocampus is a clue to obesity-associated
depression. Leptin administration induces antidepressive behav-
ior in normal mice and increased the antidepressive effect
in leptin-overexpressing transgenic mice with hyperleptinemia
(Yamada et al., 2011). Also, leptin exhibit an antidepressant-
like efficacy and ameliorates anxiety in ob/ob mice (Asakawa
et al., 2003). By contrast, leptin-deficient ob/ob mice display
more severely depressive behavior during the FST than do nor-
mal mice, and leptin administration substantially ameliorates this
depressive behavior (Lu, 2007; Yamada et al., 2011).
Taking together, leptin replacement therapy could be ther-
apeutic opportunities not only for obesity and diabetes,
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but also for obesity-related depression and anxiety (Johnston
et al., 2011).
CONCLUSION
The control of food intake, energy expenditure, and glucose
metabolism is controlled by a complex regulatory network that
depends on central and peripheral crosstalk, such as found in
brain-adipo signaling. The interactions between adiposity and the
central neuropeptidergic cascade downstream of leptin and the
role of leptin in glucose metabolism have been revealed.
Leptin gene therapy improves type1 and type2 dia-
betes and diet-induced obesity in animal models, such as
ob/ob, diet-induced obese mice, insulin-deficient type 1
diabetes mice, and insulin-dependent diabetes animals. In
contrast, obese hyperleptinemic patients with or without
type 2 diabetes do not respond to exogenously administered
r-metHuLeptin. Further studies are necessary for the clinical
use of the leptin therapy, and leptin gene therapy is expected
to be an effective therapeutic option for obesity, diabetes,
depression.
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